Immune Checkpoint Inhibitors for Cancer

This trial aims to understand how immune checkpoint inhibitors (ICIs), a type of cancer treatment, might affect liver processing of other medications. Researchers are investigating whether ICIs alter the liver's handling of various drugs, potentially leading to unexpected side effects. Participants will receive a mix of seven FDA-approved drugs to observe liver processing during ICI treatment. Individuals diagnosed with cancer and beginning treatment that includes ICIs may be suitable for this study. As an Early Phase 1 trial, this research focuses on how ICIs interact with other drugs in the body, offering participants a chance to contribute to groundbreaking insights.

The trial requires you to stop taking certain medications, especially systemic immunosuppressants and drugs that affect liver enzymes, at least 7 days before starting the study. It's best to discuss your current medications with the trial team to see if any need to be paused.

Research shows that certain cancer treatments, known as immune checkpoint inhibitors (ICIs), can extend patients' lives. However, they can also cause side effects called immune-related adverse events (irAEs). Some studies suggest that patients with these side effects might experience different survival outcomes, but this can vary.

One study found that patients with irAEs generally continued their treatment without significant delays and tolerated ICIs well. Another study suggested a possible link between these side effects and better overall survival, although this isn't always the case.

Researchers are excited about immune checkpoint inhibitors (ICI) for cancer treatment because they offer a novel approach to fighting cancer by harnessing the body's own immune system. Unlike standard chemotherapy or radiation, which directly target cancer cells, ICIs work by blocking proteins that prevent the immune system from recognizing and attacking cancer cells. This allows the immune system to better detect and destroy cancer. Additionally, ICIs have shown promise in treating a variety of cancers and may lead to more durable responses, meaning the effects could last longer than with traditional treatments. This innovative mechanism of action and potential for lasting impact make ICIs a highly anticipated development in cancer therapy.

Research has shown that immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment outcomes for many patients. Studies indicate that these drugs can lead to response rates of 40% to 70% in certain cancers, such as melanoma and Hodgkin's disease. This means many patients experience tumor shrinkage or a slowdown in disease progression. ICIs enhance the immune system's ability to identify and attack cancer cells, potentially extending patients' lives. However, ICIs can also cause serious side effects, partly due to interactions with other medications processed by the liver. In this trial, participants in Cohort 1 will receive CYP enzyme/drug transporter probe substrates at two study visits: one before starting ICI therapy and one during therapy. Participants in Cohort 2 will receive these substrates during ICI therapy at one study visit.¹⁶⁷⁸⁹